[HTML][HTML] Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma

…, N Saijo, P Sunpaweravong, B Han… - … England Journal of …, 2009 - Mass Medical Soc
Background Previous, uncontrolled studies have suggested that first-line treatment with
gefitinib would be efficacious in selected patients with non–small-cell lung cancer. Methods In …

[PDF][PDF] BEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in …

…, X Liu, Y Zhu, S Lu, J Feng, J He, B Han… - Journal of clinical …, 2015 - researchgate.net
… Provision of study materials or patients: Caicun Zhou, Baohui Han, … Caicun Zhou,
Shanghai Pulmonary Hospital, Tongji University School of Medicine; Shun Lu and Baohui Han …

First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive NSCLC

…, M Pérol, E Arriola, S Novello, B Han… - … England Journal of …, 2023 - Mass Medical Soc
Background Selpercatinib, a highly selective potent and brain-penetrant RET inhibitor, was
shown to have efficacy in patients with advanced RET fusion–positive non–small-cell lung …

Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non–small cell lung cancer: the ALTER 0303 phase 3 randomized …

B Han, K Li, Q Wang, L Zhang, J Shi, Z Wang… - JAMA …, 2018 - jamanetwork.com
Importance Anlotinib is a novel multitarget tyrosine kinase inhibitor for tumor angiogenesis
and proliferative signaling. A phase 2 trial showed anlotinib to improve progression-free …

[HTML][HTML] Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC: a randomized …

Y Yang, Z Wang, J Fang, Q Yu, B Han, S Cang… - Journal of Thoracic …, 2020 - Elsevier
Introduction Sintilimab, an anti–programmed death 1 antibody, plus pemetrexed and
platinum had revealed promising efficacy for nonsquamous NSCLC in a phase 1b study. We …

Phase III trial of ipilimumab combined with paclitaxel and carboplatin in advanced squamous non-small-cell lung cancer

…, P Gonzalez Mella, F Barlesi, B Han… - Journal of Clinical …, 2017 - eprints.qut.edu.au
Purpose Patients with squamous non-small-cell lung cancer (NSCLC) have poor prognosis
and limited treatment options. This randomized, double-blind, phase III study investigated …

Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre …

L Zhang, S Ma, X Song, B Han, Y Cheng… - The lancet …, 2012 - thelancet.com
Background Maintenance treatment of patients with advanced non-small-cell lung cancer (NSCLC)
without disease progression after first-line chemotherapy is a subject of ongoing …

[HTML][HTML] Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)

B Han, K Li, Y Zhao, B Li, Y Cheng, J Zhou, Y Lu… - British journal of …, 2018 - nature.com
Background: Anlotinib (AL3818) is a novel multitarget tyrosine kinase inhibitor, inhibiting
tumour angiogenesis and proliferative signalling. The objective of this study was to assess the …

[HTML][HTML] Chinese experts' consensus on the Internet of Things-aided diagnosis and treatment of coronavirus disease 2019 (COVID-19)

…, R Chen, J Zhou, Y Song, X Zhou, H Zhu, B Han… - Clinical eHealth, 2020 - Elsevier
The aim is to diagnose COVID-19 earlier and to improve its treatment by applying medical
technology, the “COVID-19 Intelligent Diagnosis and Treatment Assistant Program (nCapp)” …

[HTML][HTML] Phase 1b study of sintilimab plus anlotinib as first-line therapy in patients with advanced NSCLC

…, H Qiang, W Nie, Y Zhao, Y Han, Y Chen, B Han - Journal of Thoracic …, 2021 - Elsevier
Introduction Although the interaction between tumor immune microenvironment and
angiogenesis has been well established, evidence supporting the chemo-free combination of …